Gabriella C Squeo1, Courtney M Lattimore1, Nicole L Simone2, Greg Suralik3, Sunil W Dutta3, Michael D Schad3, Lucy Su3, Bruce Libby3, Einsley-Marie Janowski3, Shayna L Showalter1, Jennifer M Lobo4, Timothy N Showalter5. 1. Division of Breast and Melanoma Surgery, Department of Surgery, University of Virginia School of Medicine, Charlottesville, VA. 2. Department of Radiation Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA. 3. Department of Radiation Oncology, University of Virginia School of Medicine, Charlottesville, VA. 4. Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA. 5. Department of Radiation Oncology, University of Virginia School of Medicine, Charlottesville, VA. Electronic address: tns3b@virginia.edu.
Abstract
INTRODUCTION: Precision breast intraoperative radiation therapy (PB-IORT) is a novel approach to adjuvant radiation therapy for early-stage breast cancer performed as part of a phase II clinical trial at two institutions. One institution performs the entire procedure in an integrated brachytherapy suite which contains a CT-on-rails imaging unit and full anesthesia capabilities. At the other, breast conserving surgery and radiation therapy take place in two separate locations. Here, we utilize time-driven activity-based costing (TDABC) to compare these two models for the delivery of PB-IORT. METHODS: Process maps were created to describe each step required to deliver PB-IORT at each institution, including personnel, equipment, and supplies. Time investment was estimated for each step. The capacity cost rate was determined for each resource, and total costs of care were then calculated by multiplying the capacity cost rates by the time estimate for the process step and adding any additional product costs. RESULTS: PB-IORT costs less to deliver at a distributed facility, as is more commonly available, than an integrated brachytherapy suite ($3,262.22 vs. $3,996.01). The largest source of costs in both settings ($2,400) was consumable supplies, including the brachytherapy balloon applicator. The difference in costs for the two facility types was driven by personnel costs ($1,263.41 vs. $764.89). In the integrated facility, increased time required by radiation oncology nursing and the anesthesia attending translated to the greatest increases in cost. Equipment costs were also slightly higher in the integrated suite setting ($332.60 vs. $97.33). CONCLUSIONS: The overall cost of care is higher when utilizing an integrated brachytherapy suite to deliver PB-IORT. This was primarily driven by additional personnel costs from nursing and anesthesia, although the greatest cost of delivery in both settings was the disposable brachytherapy applicator. These differences in cost must be balanced against the potential impact on patient experience with these approaches.
INTRODUCTION: Precision breast intraoperative radiation therapy (PB-IORT) is a novel approach to adjuvant radiation therapy for early-stage breast cancer performed as part of a phase II clinical trial at two institutions. One institution performs the entire procedure in an integrated brachytherapy suite which contains a CT-on-rails imaging unit and full anesthesia capabilities. At the other, breast conserving surgery and radiation therapy take place in two separate locations. Here, we utilize time-driven activity-based costing (TDABC) to compare these two models for the delivery of PB-IORT. METHODS: Process maps were created to describe each step required to deliver PB-IORT at each institution, including personnel, equipment, and supplies. Time investment was estimated for each step. The capacity cost rate was determined for each resource, and total costs of care were then calculated by multiplying the capacity cost rates by the time estimate for the process step and adding any additional product costs. RESULTS: PB-IORT costs less to deliver at a distributed facility, as is more commonly available, than an integrated brachytherapy suite ($3,262.22 vs. $3,996.01). The largest source of costs in both settings ($2,400) was consumable supplies, including the brachytherapy balloon applicator. The difference in costs for the two facility types was driven by personnel costs ($1,263.41 vs. $764.89). In the integrated facility, increased time required by radiation oncology nursing and the anesthesia attending translated to the greatest increases in cost. Equipment costs were also slightly higher in the integrated suite setting ($332.60 vs. $97.33). CONCLUSIONS: The overall cost of care is higher when utilizing an integrated brachytherapy suite to deliver PB-IORT. This was primarily driven by additional personnel costs from nursing and anesthesia, although the greatest cost of delivery in both settings was the disposable brachytherapy applicator. These differences in cost must be balanced against the potential impact on patient experience with these approaches.
Authors: Daniel M Trifiletti; Ryan Jones; Shayna L Showalter; Bruce B Libby; David R Brenin; Anneke Schroen; Monica M Morris; Kelli A Reardon; Timothy N Showalter Journal: Future Oncol Date: 2015 Impact factor: 3.404
Authors: Sunil W Dutta; Kristine Bauer-Nilsen; Jason C Sanders; Daniel M Trifiletti; Bruce Libby; Donna H Lash; Melody Lain; Deborah Christodoulou; Constance Hodge; Timothy N Showalter Journal: Brachytherapy Date: 2018-03-05 Impact factor: 2.362
Authors: Sunil W Dutta; J Hunter Mehaffey; Jason C Sanders; Max O Meneveau; Courtney Lattimore; Bruce Libby; David R Brenin; Anneke T Schroen; Einsley M Janowski; Carl Lynch; Donna J Lash; Timothy N Showalter; Shayna L Showalter Journal: Brachytherapy Date: 2019-03-04 Impact factor: 2.362
Authors: Gabrielle B Rocque; Courtney P Williams; Kelly M Kenzik; Bradford E Jackson; Andres Azuero; Karina I Halilova; Stacey A Ingram; Maria Pisu; Andres Forero; Smita Bhatia Journal: Cancer Date: 2018-10-14 Impact factor: 6.860
Authors: Shayna L Showalter; Gina Petroni; Daniel M Trifiletti; Bruce Libby; Anneke T Schroen; David R Brenin; Parchayi Dalal; Mark Smolkin; Kelli A Reardon; Timothy N Showalter Journal: Int J Radiat Oncol Biol Phys Date: 2016-05-07 Impact factor: 7.038
Authors: Angela B Mariotto; Lindsey Enewold; Jingxuan Zhao; Christopher A Zeruto; K Robin Yabroff Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-06-10 Impact factor: 4.090